This study investigates pancreatic neuroendocrine tumors. It evaluates the effects of combining two investigational medications to understand their safety and how well they work together.
The study focuses on evaluating the safety and effectiveness of the investigational medications. It observes how these medications might work in treating the condition.
- Who can participate: Adults aged 18 and older with confirmed pancreatic neuroendocrine tumors that cannot be surgically removed can participate. Key factors include having measurable disease, an ECOG performance status, and specific disease progression criteria.
- Study details: Participants will take the investigational medications in a specific sequence.
- Study timelines and visits: The study will last 8 weeks. The study requires 4 visits.
How understandable was the trial content above?
Hard to understand
Easy to understand